OBJECTIVES: This study reviews survival outcomes and cost of lung cancer care over multiple decades at a single high-volume institution.
INTRODUCTION
Lung cancer remains the most lethal cancer in the world [1] . Detection over the past three decades has improved with the ubiquitous use and access to high-resolution diagnostic chest computed tomography (CT) and positron emission tomography. Population studies have demonstrated improved survival since 1980 in surgically resected non-small-cell lung cancer (NSCLC) [2, 3] . Adjuvant chemotherapy has made modest impacts on Stages II and III NSCLC [4] . Technological advancements in radiation have been associated with improved local control in medically inoperable NSCLC [5] . Despite renewed widespread enthusiasm for earlier detection of lung cancer supported by the results of the National Lung Cancer Screening Trial [6] , the majority of newly diagnosed cases of NSCLC are advanced where therapies have little impact on survival.
Since the introduction of the Affordable Care Act in March 2010 and the subsequent Supreme Court Decision to uphold the Act in June 2012, containment of medical costs in the USA has received unprecedented scrutiny. The law includes a provision to allow Medicare to reward healthcare organizations with a share of the savings that would result from improving care quality and reducing the cost for their eligible Medicare population. Improvement in the quality of care with cost reduction has become an essential focus of many healthcare systems. Our institution established a team to study the outcomes and cost of lung cancer over a 5-year episode of care. This study analyses survival outcomes of NSCLC over three decades inclusive of both surgically resected disease and nonsurgical disease. A cost analysis was also performed on a more contemporary cohort of patients to understand the components of cost of care and any association with survival.
METHODS

Clinical data
Our institution has configured a comprehensive database to study the outcomes of cancer patients. This Super Database contains information on 173 301 patients that have been entered into a tumour registry. The tumour registry contains information on patients diagnosed with cancer at the Massachusetts General Hospital from 1900 to 2011. Medical and demographic information were derived for patients with a diagnosis of lung cancer from a Research Patient Data Repository (RPDR) including 54 388 pathology reports, 72 313 discharge reports, 1 339 157 encounter notes, 31 131 operative reports, 2 733 524 procedure notes and 376 689 radiology reports. This database contains limited data before 1980 prompting a more comprehensive survival analysis over the last three decades and a cost analysis over a contemporary era of 2004-10. This database also contains all-cause survival information from the Social Security Administration Master Death Index (which provides information on all deaths of persons who were issued with social security numbers since its inception in 1937). Cause-of-death information was obtained by linking to the Massachusetts Death Certificate Database (which contains cause-of-death information in the state of Massachusetts from 1970 to 2010).
From 1 January 1959 to 21 December 2010, a subset of 17 025 patients diagnosed with lung cancer was identified from the Super Database. This cohort was further limited to 12 361 patients with non-small-cell lung cancer. These data include detailed information on tumour size, nodal status, presence of metastatic disease, laterality, histology and grade and do not contain detailed information on patient comorbidity. Staging was determined from the fifth (effective 1986-2002), sixth (effective 2002-2009) and seventh edition (effective 2010-present) of the American Joint Committee on Cancer pathological tumor, node, metastases staging systems [7] [8] [9] . Clinical staging information was used if the pathological stage was not available. Longitudinal medical records were used to obtain smoking history, sex, race, imaging, medications, chemotherapy, surgical procedures and the use of radiation.
Cost assessment
Billing data were derived from the Transaction Solutions International (TSI)/Enterprise Performance Systems, Inc. database. This database is managed by the Finance department of Partners Healthcare Systems, Inc., and includes detailed fields of 1 356 427 cancer-related encounters. Available data identify patient level, encounter-level and charge-level details tied to billing statements including all hospital billed inpatient and outpatient services. Only bills incurred after a diagnosis of lung cancer were included. The analysis was filtered to include only patients whose first malignant tumour recorded in the Tumor Registry was NSCLC. Approximately 50% of patients diagnosed in 2005 appear in the TSI data set, and that fraction jumps to 80% in 2006. From 2007 to 2010, over 90% of Tumor Registry Lung Cancer patients have billing data available. Professional fees for surgical procedures were not included in this cost analysis. Total cost is the sum of direct and indirect (fixed and variable) costs that the hospital incurred. Cost data analysis was performed using constant dollars and did not account for inflation over the study period 2004-2010, which was estimated at 2.5% per year.
Cost assessment was performed from 2004 to 2010 using a cohort of patients diagnosed with NSCLC. The analysis was limited to patients who received surgical treatment of Stages I, II, IIIA and those who received non-surgical treatment of Stages IIIB and IV, which resulted in a final cohort of 1025 patients. Patients were stratified into cost quartiles according to stage. Total hospital costs for NSCLC care in the first year following diagnosis were also divided into quartiles. Average hospital expenses, medical services and survival were compared across quartiles.
Statistical analysis
Survival curves for overall survival were constructed with KaplanMeier (KM) and Cox proportional hazards methods for patients diagnosed in the years 1981-2010 and compared using the log-rank test. Statistical analyses were performed with the use of the R version 0.95.265 software. Overall survival was defined as the time from surgery to death from any cause based on Social Security Death Index data. Disease-free survival was defined as the time from surgery to tumour recurrence or to death from any cause based on data from medical records only. Disease-free survival curves were removed from the analysis by virtue of incomplete data. Variables were analysed as proportions, means or medians according to their nature. We created cost quartiles for similar (same stage and surgical type) patients based on total hospital costs for NSCLC care during the first year following diagnosis. Unadjusted all-cause survival curves by stage were constructed with KM methods stratified by cost quartiles and compared through log-rank tests.
RESULTS
A total of 17 025 lung cancer patients were identified from 1 January 1959 to 21 December 2010. We observed 13 964 all-cause deaths in this patient cohort. The 1-year, 5-year and 10-year all-cause mortality rates were 41, 78, and 87%, respectively. Non-small-cell lung cancer was observed in 12 361 (72.6%) patients, small cell in 2114 (12.4%) and the remaining 2550 (15%) were listed into some other category (i.e. carcinoid, sarcoma, spindle cell neoplasms etc.). Median survival was 2.5 years in patients diagnosed with NSCLC. Demographics of patients over five decades are presented in Table 1 . Lung cancer was more prevalent in males from 1960 to 1990, but incidence rates shifted over subsequent decades favouring female gender. The mean age of patients with a new diagnosis of lung cancer increased from 62 to 66 years in the last decade (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) . Squamous cell carcinoma was most prevalent in the 1960's and changed to favour adenocarcinoma in the years after 1980 (see Table 1 ). Overall survival in patients diagnosed with NSCLC ( Fig. 1) has not significantly changed (P = 0.179, log-rank) over three decades ). The 5-, 10-and 15-year survival for NSCLC patients were 27, 15 and 5%, respectively. In contrast, non-adjusted all-cause survival did improve in the subset of patients with surgically resectable NSCLC (Fig. 2) over the same three decades (P < 0.001, log-rank).
All-cause survival by stage (both surgically treated and nonsurgically treated NSCLC) was analysed from 1981 to 2010. Five-year survival in Stage I NSCLC was 62% in the oldest decade (1981-1990) and surprisingly decreased by 7% over two decades (P < 0.001, log-rank) (Fig. 3A) . Overall survival did not significantly change over time in Stage II NSCLC (P = 0.218, log-rank) (Fig. 3B) . In
Stages III and IV NSCLC ( Fig. 3C and D) , we observed a significant improvement in overall survival in the most recent decade of care (2001-2010) (P = 0.003 and P < 0.001, respectively). 
THORACIC
Since comprehensive cost data were not available for all decades in the original patient cohort, a more contemporary era (2004-2010) was used to perform cost analysis. The demographics of 3124 patients with NSCLC in this era are depicted in Table 2 and stratified by stage. Stages I and IV comprised 38 and 33% of this patient population, respectively. Five-year overall survival for Stages I, II, IIIA, IIIB and IV disease during this time period were 65, 45, 28, 15 and 5%, respectively. Females were more likely to have Stage I disease and surgery was the treatment of choice in Stages I or II NSCLC. Stage I patients were more likely to harbour >1 tumour over the study period. Stage II disease was the least common (6.8%), which is consistent with published series.
First-year medical care cost of surgical treatment of Stages I, II, IIIA and non-surgical treatment of Stages IIIB and IV was available for 1028 patients. Patients were stratified into cost quartiles according to stage (Table 3) where Q1 represents the least expensive patients and Q4 the most expensive (within any particular stage). The most expensive quartile (Q4) in each stage was associated with increased length of stay, more chemotherapy and/or radiation, and more care providers compared with less expensive quartiles. Average total first year treatment hospital costs in Stage I NSCLC varied more than 4× between Q4 and Q1 (P = 0.05). In Stage IV NSCLC, average total first year treatment hospital spending varied 16+ times between Q4 and Q1 (P < 0.001). The permonth cost of care for NSCLC was found to gradually increase in the last 12 months of life. The last month of life had the highest contribution to cost (nearly 3× the cost/month of previous months). The per-patient hospital cost for a diagnosis of NSCLC over a 5-year period was variable with a median cost of approximately $40 500. Sixty-three percent of the cost of care was expended in the first year after diagnosis. Although the subpopulation of patients from whom these values were extracted contains many surviving patients, the distribution of cost might be expected to change as this population matures.
Survival analyses of first-year treatment hospital cost quartiles risk-adjusted for age, sex and race showed significance in the fourth quartile of Stages I and IV NSCLC (Fig. 4) . The analysis was limited to patients whose first and only tumour was NSCLC diagnosed and treated at our institution from 2004 to 2010. Among Stage I NSCLC patients treated with surgery, higher spending was significantly associated (P = 0.05) with shorter survival (Fig. 4A ). In contrast, among patients harbouring Stage IV NSCLC (Fig. 4B ) more spending (Q3 and Q4) was significantly associated (P < 0.001) with longer survival. There were no statistically significant associations with spending and survival in Stages II, IIIA or IIIB.
Components of cost in the period 2004-1010 were analysed for all patients diagnosed with NSCLC (Fig. 5) . The greatest single category of expense was chemotherapy (31%), followed by surgery (24%), inpatient medical (17%), radiation therapy (12%) and diagnostics (5%). For surgically treated patients, Stage II-IV costs were found to be roughly twice Stage I costs.
DISCUSSION
Lung cancer globally is often diagnosed at an advanced stage. The 5-year survival rate for all patients with lung cancer in the USA is still 16% (small-cell lung cancer included), only a few percentage points improved compared with survival reported in 1975-1977 [10] . Five-year survival in other countries is very variable ranging from 4.6% in Malta, 8.2% in Scotland, 16.3% in Belgium and 21% for females in South Korea [11, 12] . Globally, gender affects outcomes where men have worse 5-year survival (14%) compared with women ( 18%) [13] . The lack of evident improvement in survival of patients diagnosed with NSCLC over three decades invokes the argument to invest in resources for lung cancer prevention and smoking cessation. These efforts have been implemented by the World Health Organization entitled MPOWER, which is a comprehensive tobacco control programme [14] . MPOWER includes Monitoring the epidemic, Protecting nonsmokers from exposure to second-hand smoke, Warning smokers of the health effects of smoking with strong health warnings, Enforcing advertising bans and Raising the price of tobacco products.
There are very few publications that describe time trends of survival in NSCLC that are inclusive of all patients harbouring Stages THORACIC I-IV. Population studies from Europe [2] , Scandinavia [15] and Japan [3] report improved overall survival in surgically treated patients with NSCLC since 1980. We similarly observed improved survival over the last three decades in patients primarily treated with pulmonary resection. In contrast, when we combined all patients (inclusive of all treatment modalities) with a diagnosis of NSCLC, there was no evident improvement over the past three decades in the all-cause death rates seen at 5 and 10 years after diagnosis ( 27% survival at 5 years, 15% at 10 years and 5% at 15 years). We detected a modest reduction in the death rate measured at 1 year after diagnosis, but the fact that this difference was not observed at 5 and 10 years suggests that the reduction seen in Year 1 may be attributed to lead time-bias, where lung cancers may be diagnosed earlier due to improved detection. Compared with historical decades, the 2001-2010 decade showed worse overall unadjusted survival in Stage I NSCLC. This surprising trend may be explained by a more elderly population with cumulative morbidities. Disease-free survival and characterization of patient comorbidity would be ideal in this setting but the data were absent or difficult to confirm in all three decades. Although the absolute number of surgical cases for NSCLC increased by 57% over the past three decades (1981-2010), we did not observe any appreciable difference in the number of cases that were deemed resectable (all stages range 52-55%) over this same period. It is also likely that average life expectancy of the 2001-2010 cohort would be longer relative to that of the [1981] [1982] [1983] [1984] [1985] [1986] [1987] [1988] [1989] [1990] , thus potentially increasing the number of newly diagnosed medically inoperable Stage I NSCLC. Interestingly, the most expensive cohort of patients diagnosed with Stage I NSCLC had the worst survival. This phenomenon speaks to more complicated patients, more complex surgery, longer hospital stays and more frequent use of adjuvant therapies such as radiation or chemotherapy depicted in Table 3 .
Stage III and IV patients in our study cohort had improved survival in the most recent decade. This observation can be attributed to better staging, more aggressive implementation of multimodal therapies and perhaps better detection of patients harbouring actionable tumour mutations in advanced NSCLC. Our institution is a regional referral centre for lung cancer genotyping, thus enriching the population of Stage IV patients placed on targeted therapy. This phenomenon is also congruent with our observation that the most expensive cohort of Stage IV patients realizes the best survival. The targeted therapies are costly, improve survival, but are nearly always associated with eventual failure by virtue of acquired resistance to therapy [16] .
Contrary to perception, the largest component of cost to the care of all patients diagnosed with NSCLC is chemotherapy and not surgery or diagnostic imaging modalities. Standardization of chemotherapy regimens for appropriate patients may provide an avenue for cost savings. This is a strategy that we have embraced at our institution. We also found that a cost analysis using patient and physician-identified billing data may provide insight into practice patterns that lead to unnecessary high spending without improving healthcare outcomes. When analysing costs associated with surgical intervention, we observed very little cost variation across all nine thoracic surgeons at our institution. Of note, patients who were diagnosed with and treated for NSCLC at our institution cost 1/3 less than patients diagnosed elsewhere and then treated at our institution. The 10% of patients with the highest cost have an average cost that is five times that in the case of the median patient.
These data have recognized limitations including the absence of cancer-specific mortality which can address the weakness of overall survival analyses. Spending related to treatments outside of our institution would not be captured in this analysis. Comorbidity is not incorporated in the survival or cost analysis. All patients with previous tumours were excluded from this study to improve the quality of survival data.
CONCLUSION
Survival trends for all comers diagnosed with NSCLC have not significantly changed at our institution over three decades. This sobering phenomenon speaks to the limited efficacy of our best treatment strategies. As governments embrace low-dose CT screening for lung cancer, we will see more Stage I NSCLC where surgery can make an impact on survival as demonstrated in this study. Improving the quality of care is paramount when understanding cost data. These data provide opportunity to consider standardizing the use of chemotherapy, surgery, radiation, radiographic follow-up and care management in the last month of life.
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APPENDIX. CONFERENCE DISCUSSION
Dr A. Toker (Istanbul, Turkey): Thank you, Dr. Lanuti, for the interesting and partially disappointing data. What does your government say if they see this data?
Dr Lanuti: I don't think the government has seen it yet, but I would say that we are making an impact on stage I patients, and we will make more of an impact with the implementation of screening low dose chest CT scans. With stage IV patients we are not making a huge impact, although we are spending more money to keep them alive. Our institution has a large referral of patients who harbour targetable mutations, so we are using a lot of new drugs that are expensive. The use of expensive drugs might be something that's going to be contained.
Dr H. Eid (Dubai, United Arab Emirates): From your presentation I feel that such a group which costs the economy too much with poor prognosis and stage IV disease, is it better not to treat them or to use this money for prophylaxis? Instead of spending too much money on inventing or introducing new chemotherapeutic drugs, I'd prefer that this money was used for finding ways to prevent lung cancer, which is not treated enough; lung cancer is not treated. We have patients with stage 2, stage 3, stage 4; they have recurrence, they have low five-year survivals of 25-30%. It is not a treatment. We don't treat lung cancer. So instead of spending money on chemotherapeutics and industry, this money could be used for finding a way to avoid or prevent cancer.
Dr Lanuti: Thank you for your comments. I think cancer prevention strategies are something that we don't spend enough attention on, in lung cancer particularly.
Dr J. Schirren (Wiesbaden, Germany): A very nice presentation, but I cannot agree with your conclusion. You showed us over three decades that surgery has not developed, and I think for a thoracic surgery congress, it is very important to define the progress in thoracic surgery. You showed us that we should standardize chemotherapy, radiation and so on. I would say we also have to standardize surgery. I think in the beginning, in the first decade, the kind of lymph node dissection, the kind of working up of the pathologist, resections and so on, this is a development, this is a running project, and therefore your conclusion showed us no progress. And I would say, please say we have to standardize surgery, and if we have a very good standardization in surgery, then we can do very good multicentre studies. This we need for our representation.
Dr Lanuti: These are important comments. I would like to address two issues. I agree that I may not have shown enough data for the surgeons in the audience, and I couldn't go through all the data. We did identify improved survival In stage I NSCLC patients over the decades with surgical use only. The curves that I presented included both surgical and nonsurgical patients. Second, it turns out when you really drill down on the costs of the nine surgeons at our institution, we are pretty close. The variability of costs per surgeon was very similar without significant outliers So I don't know if there is a lot for us to save in terms of money, but when you look at the chemotherapy costs and the radiation, they had much more variability in their costs. So the surgeons were rather tight in terms of their resource implementation.
Dr S. Cassivi (Rochester, MN, USA): Mike, you are from one of the flagship institutions of North America, and really the world, so this is important data. You are to be congratulated because you looked at all-comers, it is not just a surgical series, and I think that is the context, as you have just said, of some of those results. It is stage I operated and nonoperated, and it's comforting somewhat to hear that the subset of the operated group is improving.
One of the take-home messages that you are emphasizing in this data that you presented is that cost, especially probably in the surgical group, is related to length of stay. My question to you is, have you instituted a form of protocol to standardize the trajectory of care for a patient going through lung cancer diagnosis, treatment and care?
Dr Lanuti: That's a good question. Years ago there was a period of time where the surgeons would focus on improving their length of stay, and then that lost enthusiasm. In the more recent era we are looking at length of stay and other measures, such as encouraging VATS lobectomy in appropriate patients, to reduce hospital stay. Do you force all your surgeons to do VATS lobectomies? I guess you could consider that. The better strategy is to have your surgeons who perform open lobectomies implement strategies to get people out of the hospital faster (ie remove epidural or chest tubes sooner), and that's how we approach it. We are not forcing surgeons to do VATS lobectomies, but we are going to look on both sides to improve length of stay.
Dr C. Satur (Stoke, UK): I am going to disagree with your conclusions as well, for the reason that I think the view that you are taking is more negative than your data suggests. At the end of the day, we are part of a multidisciplinary team, and I think your data clearly demonstrates the effects of a multidisciplinary team over the decades. One of the major drivers that we have had across the world is the use of a multidisciplinary team to tackle cancer, and your data very clearly demonstrates an improvement in the identification of people who have lung cancer. The numbers being identified have gone up astronomically. Okay, the proportions being identified may not be any different, but the actual numbers of people being identified are vastly better. And so if you did have a measure 30 years ago of how many people had cancer and how many people were diagnosed, I suspect you would be finding in this day and age we were diagnosing far greater numbers of the baseline number of patients with cancer than we were 30 years ago.
So overall, I think your presentation is one of success of the team, and if we try and just break it down to individual surgeons, what do we do? As surgeons, then it's a bit of a negative, but even then, the number of patients we are treating is vastly greater. And most of the money that we have poured into surgery over the last few years is actually into improving technology to identify the cancer and actually diagnosing these cancers, which we just didn't have 30 years ago.
Dr Lanuti: Thank you for those important comments. I agree it is a shifting denominator over the decades.
Dr T. Sakuragi (Saga, Japan): Do you think that there is a possibility of staging migration in stage I patients, because you have a very long term for comparing three decades? I am very interested in that.
Dr Lanuti: There is no doubt that there is stage migration in stage I, defined by better detection and better staging modalities over the decades. If you are implying that stage migration contributes to worse survival in the last decade, I agree with you.
Dr Sakuragi: Yes. You commented that the economy had problems. It is very difficult to find out the real stage.
